‘Digital twins’ project will help clean up space junk, repair and decommission spacecrafts – University of California

Imagine Earth from space: a blue marble, a pristine orb that is our one and only home. But like many other places on the planet itself, this view is littered with the evidence of humans: in the earths orbit floats more than 30,000 individual pieces of space debris larger than 10 cm, according to a 2023 report from the European Space Agency.

A new project led by Ricardo Sanfelice, UC Santa Cruz Professor and Department Chair of Electrical and Computer Engineering, will develop technology for better spacecraft that use complex robotics to clean up space debris, as well as repair, refuel and decommission other spacecraft. A research team will create highly detailed digital twin models of spacecraft that can carry out these complex tasks in space and develop next-generation control algorithms to manipulate those models, enabling experimentation without the costs of testing on the physical system.

Sanfelice and his research team have been awarded $2.5 million from the Air Force Office of Scientific Research (AFOSR) Space University Research Initiative (SURI) for this three-year project. Co-principal investigators include UC Santa Cruz Professor of Applied Mathematics Daniele Venturi, UT Austin Professor of Aerospace Engineering Karen Wilcox, and University of Michigan Professor of Aerospace Engineering Ilya Kolmanovsk; and the team will collaborate with government and industry partners including the Air Force Research Lab Space Vehicles Directorate, The University of Arizona, Raytheon Technologies, Trusted Space, Inc., and Orbital Outpost X.

A digital twin is a computer model of a physical system, designed to perfectly mimic the properties of the real-world object, including all of the instruments, computers, sensors, surrounding environment, and anything else the system might include. Digital twins enable researchers to conduct experiments and run analysis in the digital world, testing what concepts might work in the real world to determine if they are worth building and manufacturing.

Unlike more traditional simulations, digital twins often incorporate machine learning that allows the system to improve itself through experimentations, providing valuable iteration to build a more accurate and detailed system.

Digital twins can be useful in a range of engineering disciplines, but are particularly relevant for aerospace engineering where the costs associated with building the real systems are so high.

You can accelerate your production, you can reduce time and costs and risk of spacecraft design because spacecraft technology is very expensive and requires a lot of certification and regulation before they can go into space, Sanfelice said. Rather than performing those experiments which take a lot of time in the real world, with a digital twin you can do conceptual analysis and initial validation in the computer environment. This same logic extends to other complex and costly systems its all about scale and reduction of production time, cost, and risk while maintaining system performance and safety.

Digital twins are also especially useful for aerospace engineering because they allow engineers to test complex scenarios and so-called corner cases, situations where multiple parameters are at their extreme, within the realm of the computer. Highly complex and extreme situations are more likely to occur in the harsh conditions of space, and cant be fully replicated for experimentation back on Earth.

The models will enable the researchers to deeply examine what is necessary to carry out the highly complex tasks of clearing up space debris and using a spacecraft to refuel, repair, or demission other spacecraft. Such tasks could include a situation where a robotic arm on one spacecraft is trained to grab another spacecraft that is malfunctioning and tumbling through space, potentially damaging one or both of the systems. The researchers need to teach the computers to handle the tumbling and steering, developing optimization-based techniques to quickly compute and solve unexpected problems as they arise while also allowing for possible human intervention.

Sanfelice and his Hybrid Systems Lab will focus on developing the control algorithms that allow for experimentation on the spacecraft digital twins. The digital twin models need to be so complex to fully encapsulate the physics and computing variables of the real-world systems they represent, and this in turn requires new methods to control the models that go beyond the current state-of-the-art.

I have this massive detailed model of my system, it keeps updating as the system evolves and I run experiments can I write an algorithm that makes the digital twin do what I want it to do, and as a consequence hopefully the real physical system will do the same? Sanfelice said.

Sanfelices work will center around developing model predictive control algorithms, a type of optimization-based control scheme, to control the digital twins, of which Wilcox will lead the creation. Sanfelices lab develops robotic manipulators for grasping and other tasks performed by robotics, which require hybrid control schemes to enable the robotic fingers to be able to transition between conditions of contact and no contact with the object they are manipulating.

While the model predictive control techniques they develop for this project will be highly relevant to aerospace applications, Sanfelice believes there is an opportunity to expand to other complex application areas and develop more advanced basic science for digital twins and their control.

Continue reading here:

'Digital twins' project will help clean up space junk, repair and decommission spacecrafts - University of California

Sharing Innovations in Psoriasis Biologics and Uplifting Women in Dermatology – Dermatology Times

I'm going to walk the team through the head-to-head clinical trial data, but also the real-world data because the reality is a drug may perform beautifully in a controlled clinical trial setting, but the real world is messy, so that drug may not perform in the same way. I'm going to guide the attendees on which drugs offer the best durability of response over time. Spoiler alert: the IL-23's have really held up not only from an efficacy standpoint, but also from a safety standpoint over time, said Mona Shahriari, MD, FAAD, in an interview with Dermatology Times at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.

Shahriari, an assistant clinical professor of dermatology at the Yale School of Medicine and the associate director of clinical trials at CCD Research in Connecticut, presented pearls from her AAD session, Comparative Efficacy and Relative Ranking of Psoriasis Biologics Using Real-world and Clinical Trial Data. Shahriari reviewed the efficacy of various biologics and systemics for psoriasis in both clinical trials and real-world examples. Shahriari also reviewed the efficacy of biosimilars and their success.

At AAD, Shahriari also participated in a panel during Bristol Myers Squibbs Women Connection Forum. Shahriari spoke alongside Latanya Benjamin, MD, FAAD, FAAP; Alexandra Golant, MD, FAAD; and Jenny Murase, MD, FAAD, to share their personal and professional journeys, as well as advice for women in dermatology.

If there's something that you want, it's okay to ask. I think a lot of times as women, we assume that certain opportunities are given to us based on our credentials, people look at our CV, people look at everything that we've done. But that's not always the case. Sometimes people don't even know that you're interested in activity. I learned that if there was something I was interested in, if I just asked and said, Hey, I just want to throw my name in the hat for XYZ opportunity that's coming up, they've actually looked at me more carefully, and I've been able to partake in that opportunity, said Shahriari when sharing her advice for women wanting to advance in dermatology.

Transcript

Mona Shahriari, MD, FAAD: Hi, my name is Mona Shahriari. I'm an assistant clinical professor of dermatology at Yale University and the associate director of clinical trials at CCD research.

Dermatology Times: What pearls are you sharing during your session, "Comparative efficacy and relative ranking of psoriasis biologics using real-world and clinical data?"

Shahriari: At this year's American Academy of Dermatology meeting, I'm going to be doing a talk that looks at the comparative effectiveness of different biologics and systemics for plaque psoriasis, not only in clinical trial data, but also in real-world data, because we have a busy toolbox of medications. And sometimes, it's tough to know which drug do I reach for first, and if that fails, which drug do I reach for a second? I'm going to really walk the team through the head-to-head clinical trial data, but also the real-world data, because the reality is a drug may perform beautifully in a controlled clinical trial setting, but the real world is messy, so that drug may not perform in the same way. I'm going to guide the attendees on which drugs offer the best durability of response over time. Spoiler alert the IL-23's have really held up not only from an efficacy standpoint, but from a safety standpoint over time. And interestingly, some of our biosimilars have proven to be just as good as our originator drugs. So,we'll walk through the nitty gritty of those details.

Dermatology Times: What other topics or sessions are you looking forward to at AAD?

Shahriari: Well, I have to say the late breaker session is always my absolute favorite. I make sure not to miss that because being on the cutting edge of clinical trials and dermatology research, I want to make sure I'm offering my patients the most innovative treatment for their skin disease. So that is a session I do not miss because I want to make sure I know what the rest of 2024 is going to look like. But also, the JAK Inhibitors: A New Frontier, that was a new session that hit the space last year, heavily attended, and JAK inhibitors are revolutionizing how we treat so many different diseases within dermatology. I really want to see what else is out there on the horizon, and how we can bring this amazing therapy to our patients.

Dermatology Times: What is the significance of the Bristol Myers Squibb Women's Forum Panel that you participated in?

Shahriari: Well, I really think this is a landmark connection form that they put together, because the reality is as women not only in dermatology, but also as career women out there, there are definitely some disparities that go on, whether it's related to pay, whether it's related to promotion, or really just getting your name out there and exposure. And really, the purpose of this woman's connection forum is to not only help us gain connections with other women leaders within the field, and have those friendships develop and networking opportunities develop, but also to hear about the struggles of other women. Sometimes when you normalize it, and you have somebody who you look up to tell you, "You know what, I went through the same challenges. And this is how I overcame them." It can really help you feel closer to those individuals. But also, you realize everybody's human, everyone's going to face challenges, and what can you do to overcome those challenges and not let them get you down?

Dermatology Times: What advice do you have for other women in dermatology?

Shahriari: I really think the 2 main pieces of advice I have is to find a good mentorship network. And I'm calling it a network and not a mentor because in different stages of your life and different aspects of your career, you're going to need different people. And that mentor might be a female, that mentor might be a male. You want to find different individuals to include in that network of yours so you'll have individuals to go through. But also, one other piece of advice I have is if there's something that you want, it's okay to ask. I think a lot of times as women, we assume that certain opportunities are given to us based on our credentials, people look at our CV, people look at everything that we've done. But that's not always the case. Sometimes people don't even know that you're interested in an activity. And I really learned that if there was something I was interested in, if I just asked and said, "Hey, I just want to throw my name in the hat for XYZ opportunity that's coming up, "they've actually looked at me more carefully, and I've been able to partake in that opportunity. So that was one of the simplest pieces of advice I got once upon a time. And it's really done well for me.

Dermatology Times: What positive changes have you seen in dermatology?

Shahriari: I think one thing I've noticed is historically, as a specialty, we used to prescribe a lot of topical agents for our patients. But we've had an explosion of oral and injectable medications for the treatment of various diseases. And I've been really pleased to find a lot of my colleagues jumping on the bandwagon to offer patients some of these newer therapies because sometimes as dermatologists we do want to see more safety data, we do want to see more efficacy data. But I think the value of these newer generation medications, not only from an efficacy standpoint, but also from a safety standpoint is becoming more evident. So, to see my colleagues jump on the bandwagon and offer these to the patients is really going to make a difference for our patients for years and years to come.

One other piece that I've seen is there's been a lot of emphasis on diversity within clinical trials and really allowing for our patients with skin of color to be at the forefront of many activities that we do within dermatology. Because the reality is that historically a lot of our patients with skin of color, they were not in our clinical trials. And when these individuals went to dermatology offices, they were either not getting appropriate treatment, or they were being undertreated. misdiagnosed. And many of my contemporaries and colleagues just didn't feel comfortable caring for these individuals, but as the population of the United States diversifies, and those people who are a minority today become more of the majority, I love that within dermatology, we are prioritizing the needs of these individuals so that we can take care of all of our patients across all skin tones moving forward.

[Transcript lightly edited for space and clarity.]

Read the rest here:

Sharing Innovations in Psoriasis Biologics and Uplifting Women in Dermatology - Dermatology Times